- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 14, 2021
Highlights
- Market Cap
- $48.90M
- Enterprise Value
- $46.98M
- EPS (TTM)
- -$0.34
- EBITDA (TTM)
- -$13.25M
- Year Range
- $0.03 - $0.24
- ROA (TTM)
- -362.33%
- ROE (TTM)
- 251.43%
- Avg. Volume (1M)
- 1K
- Avg. Volume Value (1M)
- $135.37
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ESLAW Performance Chart
Estrella Immunopharma Inc. (ESLAW) is up 90.0% since the beginning of the year. At $0 per share, ESLAW is trading 60.4% below its 52-week high of $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Estrella Immunopharma Inc. (ESLAW) has returned 90.00% so far this year and 110.64% over the past 12 months.
Estrella Immunopharma Inc.
- 1D
- 57.80%
- 1M
- -30.25%
- 6M
- 58.34%
- YTD
- 90.00%
- 1Y
- 110.64%
- 3Y*
- -21.98%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -23.91%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ESLAW Monthly Returns History
Based on dividend-adjusted daily data since Sep 14, 2021, ESLAW's average daily return is +1.62%, while the average monthly return is +7.72%. At this rate, an investment would double in approximately 0.8 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 2023 with a return of +188.3%, while the worst month was Sep 2022 at -68.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, ESLAW closed higher 20% of trading days. The best single day was Nov 25, 2022 with a return of +206.2%, while the worst single day was Jan 25, 2023 at -75.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.00% | 26.67% | -1.45% | 71.16% | 5.23% | -3.63% | -26.92% | 90.00% | |||||
| 2025 | -43.42% | 15.38% | 28.50% | 14.79% | -59.66% | 33.05% | -5.05% | -20.18% | 43.88% | 131.85% | -17.57% | -49.49% | -45.59% |
| 2024 | 0.66% | 32.45% | 66.12% | 3.99% | -1.74% | 1.62% | 44.93% | -0.00% | -35.70% | 42.92% | -0.98% | 0.99% | 206.33% |
| 2023 | 1.92% | 28.11% | 50.66% | -23.85% | -31.96% | 4.72% | 188.29% | -22.75% | 94.26% | -67.01% | -55.56% | -14.77% | -42.31% |
| 2022 | -42.00% | -27.59% | 6.93% | -6.48% | -24.81% | 59.78% | -32.62% | 27.88% | -68.77% | 138.88% | -56.84% | -25.71% | -89.60% |
| 2021 | 13.78% | 17.21% | 13.10% | -7.92% | 38.89% |
Benchmark Metrics
Estrella Immunopharma Inc. has an annualized alpha of 4616.25%, beta of 1.62, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 14, 2021.
- This stock participated in 167.04% of S&P 500 Index downside but only 26.16% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4,616.25%
- Beta
- 1.62
- R²
- 0.01
- Upside Capture
- 26.16%
- Downside Capture
- 167.04%
Return for Risk
Risk / Return Rank
ESLAW ranks 76 for risk / return — above 76% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Estrella Immunopharma Inc. (ESLAW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ESLAW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.92 | ||
| Sortino ratioReturn per unit of downside risk | +0.64 | ||
| Omega ratioGain probability vs. loss probability | 1.44 | 1.25 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 1.43 | 2.00 | -0.57 |
| Martin ratioReturn relative to average drawdown | 2.12 | 8.49 | -6.37 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Estrella Immunopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Estrella Immunopharma Inc. was 96.11%, occurring on Jan 25, 2023. The portfolio has not yet recovered.
The current Estrella Immunopharma Inc. drawdown is 82.88%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.11%Jan 2023 | 1y 2mo | — | 4y 8moNov 2021 - now | — |
-12.10%Oct 2021 | 1d | 4d | 4dOct 2021 - Nov 2021 | — |
-4.70%Sep 2021 | 6d | 7d | 13dSep 2021 - Oct 2021 | — |
-4.65%Oct 2021 | 9d | 2d | 11dOct 2021 - Oct 2021 | — |
-3.60%Nov 2021 | 1d | 1d | 1dNov 2021 - Nov 2021 | — |
Drawdown Indicators
| ESLAW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.11% | -56.78% | -39.33% |
Max Drawdown (1Y)Largest decline over 1 year | -78.79% | -9.10% | -69.69% |
Max Drawdown (3Y)Largest decline over 3 years | -90.50% | -18.90% | -71.60% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -82.88% | -1.58% | -81.30% |
Average DrawdownAverage peak-to-trough decline | -75.89% | -10.70% | -65.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 52.69% | 2.14% | +50.55% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Estrella Immunopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Estrella Immunopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ESLAW
Add Estrella Immunopharma Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ESLAW